Frontotemporal dementia as a comorbidity to idiopathic normal pressure hydrocephalus (iNPH): a short review of literature and an unusual case

Korhonen VE

Springer Nature
Frontotemporal dementia as a comorbidity to idiopathic normal pressure hydrocephalus (iNPH): a short review of literature and an unusual case

V. E. Korhonen1,2, E. Solje3, N. M. Suhonen4,5, T. Rauramaa6,7, R. Vanninen8, A. M. Remes3,4,5 and V. Leinonen1,2*

Abstract

Behavioural variant frontotemporal dementia (bvFTD) and idiopathic normal pressure hydrocephalus (iNPH) are neurodegenerative diseases that can present with similar symptoms. These include decline in executive functions, psychomotor slowness, and behavioural and personality changes. Ventricular enlargement is a key radiological finding in iNPH that may also be present in bvFTD caused by the C9ORF72 expansion mutation. Due to this, bvFTD has been hypothesized as a potential comorbidity to iNPH but bvFTD patients have never been identified in studies focusing in clinical comorbidities with iNPH. Here we describe a patient with the C9ORF72 expansion-associated bvFTD who also showed enlarged ventricles on brain imaging. The main clinical symptoms were severe gait disturbances and psychiatric problems with mild cognitive decline. Cerebrospinal fluid removal increased the patient’s walking speed, so a ventriculoperitoneal shunt was placed. After insertion of the shunt, there was a significant improvement in walking speed as well as mild improvement in cognitive function but not in neuropsychiatric symptoms relating to bvFTD. Comorbid iNPH should be considered in bvFTD patients who have enlarged ventricles and severely impaired gait.

Keywords: C9ORF72 repeat expansion, CSF shunt, Dementia, Idiopathic normal pressure hydrocephalus, Neurodegeneration

Background

Idiopathic normal pressure hydrocephalus (iNPH) is a progressive neurodegenerative disease that has three core symptoms: gait disturbance, cognitive impairment, and urinary incontinence [1]. Patients with iNPH may show partial or full expression of this triad of symptoms as well as impaired frontal executive function [2]. Ventriculomegaly is observed along with the clinical symptoms [3, 4].

The most common comorbidities among iNPH patients are hypertension, Alzheimer’s disease (AD) and vascular dementia [3, 5]. Amyloid beta plaques and hyperphosphorylated tau-protein inclusions have been frequently identified in neuropathological studies and studies using frontal cortical biopsies in iNPH [6–8].

Although frontotemporal dementia (FTD) has been listed routinely as a comorbidity [3, 9] in iNPH, none of the studies focusing on the comorbidities in iNPH have identified patients suffering from both of the diseases concomitantly [3, 5, 6]. In addition, none of the studies evaluating the neuropathology of iNPH patients have included, to our knowledge, immunohistochemical staining of p62 or TDP-43, which are indicative neuropathology in about half of cases with frontotemporal lobar degeneration (FTLD) spectrum.

FTLD encompasses a clinically and genetically heterogeneous group of neurodegenerative diseases. The most frequent clinical subtype is behavioural variant frontotemporal dementia (bvFTD), which presents as progressive changes in personality and behaviour and deficits in executive functions [10]. Also gait disturbance,
psychomotor slowing with extrapyramidal symptoms as well as urinary incontinence may be present.

Up to 50% of FTLD cases are familial. Mutations in microtubule-associated protein tau (MAPT), progranulin (PGRN), and expanded hexanucleotide repeat in a non-coding region of the chromosome 9 open reading frame 72 (C9ORF72) are the most common genetic causes of FTLD, together accounting for 60% of familial FTLD cases [11]. The neuropathology associated with FTLD is heterogeneous, which is not surprising considering the extensive variability seen in the clinical features and in genetics. Five major histopathological subtypes of FTLD are now recognized, but the two most common neuropathological findings are tau- or TDP-43 positive inclusions [12]. Mutations in MAPT are associated with tau-pathology and mutations in PGRN or the C9ORF72 expansion are typically associated with tau-negative but TDP-43 positive neuropathology [11, 13, 14]. The C9ORF72 expansion is the major genetic cause of FTLD [15, 16]. In Finland, the C9ORF72 repeat expansion has been reported to be the highest in the world and it has been determined to be 48% in familial FTLD [16, 17]. The most common motor presentation associated with the C9ORF72 expansion is amyotrophic lateral sclerosis (ALS) but extrapyramidal symptoms have also been reported [18].

Here we describe a patient with the C9ORF72 expansion-associated bvFTD who presented with severe gait disturbances and ventriculomegaly on brain imaging. The patient’s walking speed increased 73% after the insertion of a ventriculoperitoneal shunt, and mild cognitive improvement was also detected. In addition, the patient subjectively experienced a significant relief of her symptoms in terms of her memory and her ability to move.

Patient

A 59-year-old woman without any previous history of neurological or psychiatric diseases was referred to a neurologist due to delusions and declining performance at work. Compulsive behaviour, apathy, and hyperorality were the main neuropsychiatric symptoms. ALS and unspecified dementia had been diagnosed in first-degree relatives. Her Mini Mental Status Examination (MMSE) score was 26/30. In the neuropsychological examination, the most prominent dysfunction was found in executive function (e.g. in verbal fluency, on the clock drawing test, on the Trail Making Test B, and on the Stroop test) and in psychomotor speed (Trail Making Test A and the Digit Symbol test). In addition, her performance was poor on tests of visuospatial skills, which can be due to executive dysfunction rather than to visuospatial deficits per se [19]. The patient performed relatively well on verbal memory tests but had deterioration in her visual memory. On the frontal behavioral inventory (FBI), her next-of-kin reported mild behavioural changes, mainly apathy. Her BDI-II score did not indicate depression. bvFTD was diagnosed based on the clinical assessment, and the presence of the C9ORF72 repeat expansion (>60 repeats) confirmed the diagnosis.

Risperidone was prescribed as a treatment for her delusions, but the patient had begun to suffer from bradykinesia and shortened step length. Psychomotor slowness was also evident. Due to the extrapyramidal symptoms, risperidone was replaced with aripiprazole. Despite the mild conservative antipsychotic treatment, the patient’s extrapyramidal symptoms continued to worsen. Three years after her first contact with a neurologist, the patient began to suffer from daily urinary incontinence. [(123)I] β-CIT SPECT revealed normal I-123 uptake, excluding idiopathic Parkinson’s disease as the cause of the extrapyramidal symptoms.

MRI was performed 1 year after the onset of the first symptoms and it revealed predominantly frontal cortical atrophy and dilatation of the lateral ventricles. The parasagittal sulci were not obliterated. Hippocampal atrophy (Scheltens grade 2/4) was also present. White matter changes were mild (Fig. 1).

Despite her genetically confirmed bvFTD, the patient was referred to a neurosurgeon for iNPH evaluation due to gait difficulties, psychomotor slowness, urinary incontinence, and ventricular enlargement. The MMSE score had decreased from 26/30 to 23/30. The lumbar CSF removal (tap test) showed a 15% increase in walking speed, and the patient subjectively experienced significant relief from her gait-related symptoms. A ventriculoperitoneal shunt was placed 3 years after the onset of the first symptoms, and a frontal cortical biopsy was taken during the insertion of the intraventricular catheter. The biopsy included both white and grey matter. Immunohistochemical staining revealed a moderate level of p62 and TDP-43 immunoreactive lesions, mainly in the form of thin neurites (Fig. 2). Neither beta-amyloid nor hyperphosphorylated-tau was present.

The response to the shunt was evaluated 3 and 12 months after its implantation. At the 3-month evaluation, the patient’s walking speed in two 10 m walk tests had increased 73% from 0.18 to 0.30 m/s. Cognition was evaluated using the CERAD-NB. Improvement was seen in the MMSE score, which increased from 23/30 to 26/30, and in the score for the clock drawing test [20], which increased from 3/6 to 6/6. However, the patient’s word list learning continued to slowly deteriorate. There were no notable differences between pre-shunt and post-shunt findings for the other subtests of the CERAD-NB. Insertion of the ventriculoperitoneal shunt did not have effect on the patient’s urinary incontinence. At the 12-month
evaluation, the patient was still able to walk without any walking aids and her walking speed had remained unchanged compared to the 3-month evaluation. The patient’s MMSE score had decreased to pre-operative level (22/30) and also the neuropsychiatric symptoms including delusions, hyperorality, increased sex drive and...
disinhibition were more prominent. The urinary incontinence had remained unchanged.

**Discussion and conclusions**

This is the first report of a response to a shunt in a patient with genetically, pathologically, and clinically confirmed bvFTD. Due to the patient's prominent gait difficulties, psychomotor slowness, urinary incontinence, and enlarged ventricles, iNPH was suspected.

In iNPH gait improvement is the most prominent, frequent, and usually the earliest sign of response to a shunt compared to improvements in urinary incontinence or cognition [21]. The marked improvement of walking speed and ability to move was also seen in our patient.

A slight improvement was also detected in patient's cognitive functions after the shunt surgery. A recent meta-analysis by Peterson et al. [22] found strong evidence for improvement in iNPH patients following shunt surgery for global cognitive measure (MMSE), verbal learning and memory, and psychomotor speed. The evidence for improvement was weaker for tests of executive function. In the present case, MMSE score improved significantly. In addition, the patient showed improvement in the clock drawing subtest of the CERAD-NB, indicating possible improvement in executive functioning. However, the shunt surgery did not have a positive effect on verbal learning or memory as measured by the CERAD-NB.

The placement of the ventriculoperitoneal shunt did not have any significant effect on the urinary incontinence or the behavioural symptoms associated with bvFTD.

The differential diagnosis between bvFTD and iNPH maybe challenging due to similar clinical symptoms in both conditions. Extrapyramidal symptoms, including rigidity and bradykinesia are typical in patients with bvFTD [18]. Gait and balance disturbance as well as psychomotor slowing are prominent symptoms in iNPH [1]. Deficits in executive functions are core cognitive changes in both iNPH and bvFTD [1, 10] and neuropsychiatric symptoms are frequently detected in both diseases [23, 24]. Also, psychiatric manifestations such as depression, mania, aggression, disturbances of impulse control, obsessive–compulsive disorder, and psychosis, including paranoia and hallucinations may be seen in patients with iNPH and bvFTD [3, 9, 25]. Neuroradiological findings may also be similar in both diseases. A frontal and temporal brain atrophy is the most common feature in the C9ORF72 expansion associated bvFTD. However, sometimes central atrophy with prominent ventricular enlargement mimicking iNPH may also be present in bvFTD [18, 26].

The etiology of iNPH is still largely unknown, but the most common neuropathologies in iNPH are vascular and AD-related changes [7]. There is also increasing evidence that iNPH may have a genetic component [27–31]. We have previously observed that over 40% of iNPH patients present, on their cortical biopsies, with either beta-amyloid, hyperphosphorylated tau protein or both [8]. It has been reported that beta-amyloid and hyperphosphorylated tau protein accumulation in the brain is increased in Kaolin-aged hydrocephalic rats and it has been hypothesized that the accumulation is due to decreased CSF clearance [32, 33]. Therefore, it might be that part of the shunt response seen in iNPH patients could be due to improved clearance of solute neurotoxic molecules in the brain. However, we do not believe that already existing aggregates could be cleared from the brain. In the presented case, the shunt response is most likely due to decrease in the pressure gradient. This hypothesis is further supported by the observation that the patient's neuropsychiatric symptoms related to bvFTD worsened over time and therefore we did not observe any effect that that the potential improved CSF clearance of TDP-43 or p62 had on the shunt response in the described patient.

The present case illustrates that comorbid iNPH should be considered in bvFTD patients who have enlarged ventricles and severely impaired gait and that the relationship between iNPH and C9ORF72 expansion-associated bvFTD and the frequency of the comorbidity merit further evaluation.

**Abbreviations**

AD: Alzheimer’s disease; ALS: amytotrophic lateral sclerosis; bvFTD: behavioral variant frontotemporal dementia; CERAD-NB: Consortium to Establish a Registry for Alzheimer’s Disease Neuropsychological Battery; CHMP2B: chromosome-modifying protein 2B; CSF: Cerebrospinal fluid; FBI: frontal behavioral inventory; FTLD: frontotemporal lobar degeneration; GRN: progranulin; iNPH: idiopathic normal pressure hydrocephalus; MAPT: microtubule-associated protein tau; p62: sequestosome-1/ubiquitin-binding protein; TDP-43: TAR DNA binding protein 43.

**Authors’ contributions**

VK analyzed patient’s medical records and was the main writer of the manuscript. ES interpreted medical records and contributed to writing the manuscript. AMR analyzed medical records, examined the patient and reviewed the manuscript. VL analyzed patient records, examined the patient and reviewed the manuscript. TR analyzed the frontal cortical biopsy and reviewed the manuscript. RV interpreted the radiological imaging and reviewed the manuscript. All authors have contributed to the work and agree with the presented findings. All authors read and approved the final manuscript.

**Author details**

1. Department of Neurosurgery, Kuopio University Hospital, P.O. Box 100, 70029 KYS Kuopio, Finland.
2. University of Eastern Finland, P.O. Box 100, 70029 KYS Kuopio, Finland.
3. Institute of Clinical Medicine-Neurology, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland.
4. Medical Research Center, Oulu University Hospital, P.O. Box 20, 90029 Oulu, Finland.
5. Unit of Clinical Neuroscience, Neurology, University of Oulu, P.O. Box 5000, 90014 Oulu, Finland.
6. Institute of Clinical Medicine-Pathology, School of Medicine, University of Eastern, Kuopio, Finland.
7. Department of Pathology, Kuopio University Hospital, P.O. Box 162, 70211 Kuopio, Finland.
8. Department of Radiology, Kuopio University Hospital, P.O. Box 100, 70029 KYS Kuopio, Finland.
Acknowledgements
We wish to acknowledge RH Manita Partanen for maintaining the Kuopio University Hospital NPH-registry.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
All data relevant to the study is shown in the article.

Consent for publication
Additional informed consent was obtained from the patient for whom identifying information is included in this article.

Ethics approval and consent to participate
This study was conducted according to the Declaration of Helsinki and Kuopio University Ethics Board approved of the study. Informed consent was obtained from the patient regarding the participation of the study.

Funding
This study was funded by Kuopio University Hospital EVO-fund.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 7 February 2017    Accepted: 5 April 2017    Published online: 19 April 2017

References
1. Relkin N, Marmarou A, Klinge P, Bergsneider M, Black PM. INPH guidelines, part II: Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery. 2005;57(3):S1–22.
2. Saito M, Nishio Y, Kanno S, Uchiyama M, Hayashi A, Takagi M, et al. Cognitve profile of idiopathic normal pressure hydrocephalus. Dement Geriatr Cogn Dis Extra. 2011;1:202–11.
3. Malm J, Graff-Radford NR, Ishikawa M, Kristensen B, Leinonen V, Mori E, et al. Influence of comorbidities in idiopathic normal pressure hydrocephalus—research and clinical care. A report of the ISHCSF task force on comorbidities in INPH. Fluids Barriers CNS. 2013;10:22.
4. Williams MA, Relkin NR. Diagnosis and management of idiopathic normal-pressure hydrocephalus J Neurol Clin Pract. 2013;3:337–85.
5. Koivisto AM, Kurki M, Alafuzoff I, Sutela A, Rummukainen J, Savolainen S, et al. High risk of dementia in ventricular enlargement with normal pressure hydrocephalus related symptoms. J Alzheimer’s Dis. 2016;52:497–507.
6. Bech-Azeddine R, Haghy P, Juulier M, Gjerret F, Waldemar G. Idiopathic normal pressure hydrocephalus: clinical comorbidity correlated with cerebral biopsy findings and outcome of cerebrospinal fluid shunting. J Neurol Neurosurg Psychiatry. 2007;78:157–61.
7. Leinonen V, Koivisto AM, Savolainen S, Rummukainen J, Sutela A, Vanninen R, et al. Post-mortem findings in 10 patients with presumed normal-pressure hydrocephalus and review of the literature. Neuropathol Appl Neurobiol. 2012;38:72–86.
8. Leinonen V, Koivisto AM, Alafuzoff I, Pykk OT, Rummukainen J, Von Und Zu, Fraunberg M, et al. Cortical brain biopsy in long-term prognostication of 468 patients with possible normal pressure hydrocephalus. Neurodegener Dis. 2012;10:166–9.
9. Relkin N, Marmarou A, Klinge P, Bergsneider M, Black PM. INPH guidelines, part II: Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery. 2005;57(3 suppl):4–16.
10. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;34:2456–77.
11. Haapasalo A, Remes AM. Genetic and molecular aspects of frontotemporal lobar degeneration. Curr Genet Med Rep. 2013;3:38–18.
12. Josephs KA, Hodges JR, Snowden JS, Mackenzie IR, Neumann M, Mann DM, et al. Neurological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol. 2011;122:137–53.
13. Rademakers R, Neumann M, Mackenzie IR. Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol. 2012;8:423–34.
14. Tack P, Sanchez-Contreras M, Rademakers R, Dickson DW, Wszolek ZK. Genetic disorders with tau pathology: a review of the literature and report of two patients with tauopathy and positive family histories. Neurodegener Dis. 2016;16:12–21.
15. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in non-coding region of C9ORF72 causes chromosome 9p21-linked FTD and ALS. Neuron. 2011;72:257–68.
16. Majounie E, Renton AE, Mok K, Dopper EGP, Waite A, Rollinson S, et al. Frequency of the C9ORF72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11:323–30.
17. Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21 linked ALS-FTD. Neuron. 2011;72:257–68.
18. Kivorinine A-L, Bode MK, Paavola L, Tuominen H, Kallo M, Renton AE, et al. Clinical characteristics of C9ORF72-linked frontotemporal lobar degeneration. Dement Geriatr Cogn Dis Extra. 2013;3:251–62.
19. Possin K. Visual spatial cognition in neurodegenerative disease. Neurocase. 2010;16:466–87.
20. Leszak MD, Howieson DB, Bigler ED, Tranel D. Neuropsychological assessment. 5th ed. New York: Oxford University Press; 2012.
21. McGirt MJ, Woodworth G, Coon AL, Thomas G, Williams MA, Rigamonti D. Diagnosis, treatment, and analysis of long-term outcomes in idiopathic normal-pressure hydrocephalus. Neurosurgery. 2005;57:699–705.
22. Peterson KA, Savulich G, Jackson D, Killikelly C, Pickard JD, Sahakian BJJ. The effect of shunt surgery on neuropsychological performance in normal pressure hydrocephalus: a systematic review and meta-analysis. J Neurol. 2016;263(8):1–9.
23. Hirono N, Etsuro Mori MD, Satoshi Tanimukai MD, Hiroaki Kazui MD, Mamoru Hashimoto MD, Tokiji Hanihara MD, et al. Distinctive neurobehavorial features among neurodegenerative demetias. J Neuropsychiatr Clin Neurosci. 1999;11:498–502.
24. Kito Y, Kazui H, Kubo Y, Yoshida T, Takaya M, Wada T, et al. Neuropsychiatric symptoms in patients with idiopathic normal pressure hydrocephalus. Behav Neurol. 2009;21:165–74.
25. Solje E, Aaltokallio H, Koivumaa-Honkanen H, Suhonen NM, Moilanen V, Kiviharju A, et al. The phenotype of the C9orf72 expansion carriers according revised criteria for bvFTD. PLoS ONE. 2015;10:e0131817.
26. Mahoney CJ, Downey LE, Ridgway GR, Beck J, Clegg S, Blair M, et al. Longitudinal neuroimaging and neuropsychological profiles of frontotemporal dementia with C9ORF72 expansions. Alzheimers Res Ther. 2012;4:41.
27. Cusimano MD, Revilak D, Stuss DT, Barrera-Martinez JC, Salehi F, Freedman M. Normal-pressure hydrocephalus: is there a genetic predisposition? Can J Neurol Sci. 2011;38:274–81.
28. Takahashi Y, Kawanami T, Nagasawa H, Iseki C, Hanyu H, Kato T. Familial normal pressure hydrocephalus (NPH) with an autosomal-dominant inheritance: a novel subgroup of NPH. J Neurol Sci. 2011;308:149–51.
29. Kato T, Sato H, Emi M, Seino T, Arawaka S, Iseki C, et al. Segmental copy number loss of SFMBT1 gene in elderly individuals with ventriculomegaly: a community-based study. Intern Med. 2011;50:297–303.
30. Sato H, Takahashi Y, Kimihira L, Iseki C, Kato H, Suzuki T, et al. A segmental copy number loss of the SFMBT1 gene is a genetic risk for shunt-responsive, idiopathic normal pressure hydrocephalus (NPH): a case-control study. PLoS ONE. 2016;11:e0166615.
31. Huovinen J, Kastinen S, Komulainen S, Onnas M, Avellan C, Frantzen J, et al. Familial idiopathic normal pressure hydrocephalus. J Neurol Sci. 2016;368:11–8.
32. Silverberg GD, Miller MC, Machan JT, Johansson CE, Carapoulous IN, Pascale CL, et al. Amyloid and Tau accumulate in the brains of aged hydrocephalic rats. Brain Res. 2010;1317:286–99.
33. Silverberg GD, Miller MC, Pascale CL, Carapoulous IN, Agca Y, Agca C, et al. Kaolin-induced chronic hydrocephalus accelerates amyloid deposition and vascular disease in transgenic rats expressing high levels of human APP Fluids Barriers CNS. 2015;12:22.